Affiliation:
1. National Medical Research Center for Hematology
Abstract
Introduction. Peripheral T-cell lymphomas (PTCL) — a rare group of lymphoproliferative diseases characterized by an aggressive course and an unfavorable prognosis. The group is represented by heterogeneous nosological forms, in which standard treatment options lead to unsatisfactory results. Aim: to present the protocols for the treatment of PTCLMain findings. In total, 12 years of experience in the treatment of 724 patients with T-cell lymphomas (430 patients with primary cutaneous forms, 110 patients with leukemic variants and 184 with peripheral T-cell lymphomas) has been accumulated. The treatment results and therapeutic algorithms were analyzed. In the general group of patients, the 3-year overall survival (OS) and relapse-free survival (EFS) were 76 % and 70 %, respectively. The best treatment results were achieved in the groups of intestinal T-cell lymphoma, specifically (EATL), and angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell ALK-positive lymphoma (ALCL ALK+), and the worst — in the group of ALCL ALK- (5-year EFS 31 %). High-dose chemotherapy under the NHL BFM-90 program in the treatment of ALK+ ALCL allows achieving 10-year OS and EFS 87 % and 84 %, respectively, but the less toxic CHOEP program was not inferior in effectiveness: 5-year OS and EFS amounted to 93 % and 88 %, respectively. High survival rates of patients with EATL were achieved with the use of high-dose chemotherapy according to the LB-M-04 program followed by auto-HSCT in the first line of therapy: 5-year OS and EFS amounted to 79 % and 74 %, respectively. The positive role of AITL maintenance therapy has been shown: 5-year OS and EFS during its implementation amounted to 75 % and 49 % versus 41 % and 20 % in the absence of it. In the protocols for the treatment of extranodal NK/T cell lymphoma, radiation therapy was used in the first line of therapy, 5-year OS and EFS were 60 % and 42 %, respectively. The role of autologous hematopoietic stem cell transplantation (auto-HSCT) in all PTCL was evaluated: 5-year OS and EFS were 82 % and 58 % compared with 67 % and 49 % without auto-HSCT. The transplantation of allogeneic hematopoietic stem cells (allo-HSCT), even in the treatment of relapses of the disease, has shown its effectiveness: 9 out of 11 patients are alive and remain in remission of the disease.
Publisher
National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation
Reference42 articles.
1. Gorenkova L.G., Kovrigina A.M., Myakova N.V. et al. Nodal T-cell lymphomas Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Eds. I.V. Poddubny, V.G. Savchenko. Moscow, 2018. P. 98–105. (In Russian).
2. Swerdlow S.H., Campo E., Harris N., et al. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). Eds. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.
3. Falini B., Lazzi S., Pileri S. A comparison of the International Consensus and 5th WHO classifi cations of T-cell lymphomas and histiocytic/dendritic cell tumours. Br J Haematol. 2023; 203(3): 369–83. DOI: 10.1111/bjh.18940.
4. Fend F., van den Brand M., Groenen P.J., et al. Diagnostic and prognostic molecular pathology of lymphoid malignancies. Virchow’s Arch. 2023. DOI: 10.1007/s00428-023-03644-0.
5. Ellin F., Landström J., Jerkeman M., et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014; 124(10): 1570–7. DOI: 10.1182/blood-2014-04-573089.